The short version.
If you're a woman in your 40s researching peptide stacks, you've probably encountered protocols built around three or four compounds at once — often a GH-secretagogue (CJC-1295/ipamorelin or sermorelin), a copper peptide (GHK-Cu) for skin, NAD+ for energy, and sometimes BPC-157 or others. The framing is usually some version of "peri/post-menopause optimization."
The honest first question is upstream of the stack: have you characterized your hormones? The dominant biology in this age band is hormonal — declining estrogen, fluctuating progesterone, thyroid shifts, sometimes low ferritin. Peptides can play a supportive role, but they don't replace the conversation about HRT, sleep architecture, and metabolic labs.
The components people commonly consider.
| Component | Stated rationale | Honest caveat |
|---|---|---|
| CJC-1295 + Ipamorelin | Support GH pulses, sleep, body composition in age-related decline | Most data is mixed-sex / male-skewed; effect sizes modest |
| GHK-Cu | Topical or subq for skin remodeling, hair, wound healing | Topical evidence stronger than systemic; cosmetic role unclear |
| NAD+ | Mitochondrial support, energy, sirtuin/longevity rationale | Hormonal evaluation usually higher-yield first conversation |
| Sermorelin | Alternative GH-secretagogue with longer use history | Similar caveats to CJC-1295/ipa for women specifically |
The stack people end up with is usually narrower than the catalog suggests. A common thoughtful approach: characterize hormones first (estradiol, progesterone, FSH, thyroid panel, ferritin); decide on HRT if appropriate; layer in one or two peptides (often a GH-secretagogue and / or NAD+) once the hormonal foundation is set; reassess after 12 weeks.
The honest framing: stacking three or four peptides on day one is harder to interpret and harder to titrate than a sequenced approach. The goal is a protocol you can read, not a maximum-coverage cocktail.
The protocol you can read is better than the cocktail that hits everything. That's especially true in a transition this hormonal.
Why oversight matters.
The internet sells almost any peptide as research chemicals — vials with disclaimers, no prescription, no provider, no follow-up. The risk isn't theoretical. Sterility, peptide identity, peptide content, and contamination all vary widely between gray-market vendors. The FDA has been explicit that compounded drugs aren't FDA-approved, and that research-only labels don't protect consumers when products end up in human use.
Oversight isn't a bureaucratic checkbox. It's a U.S.-licensed prescriber who reviews your history before prescribing, a 503A compounding pharmacy that sources active pharmaceutical ingredient and prepares the medication under USP 797 sterile standards, and a follow-up cadence that lets someone catch a problem before it becomes a worse one.
How Boswell handles this.
Boswell pairs you with a U.S.-licensed physician for the intake. They review your goals, medications, history, and any contraindications before prescribing. If a protocol isn't appropriate, you don't get it. If it is, the prescription goes to a 503A compounding pharmacy that prepares the medication under sterile compounding standards, labels it for you specifically, and ships it directly.
Refills aren't automatic — they involve a check-in. The point isn't to gate access; it's to keep someone clinical in the loop while you're on therapy. How Boswell works →
Questions worth asking your provider.
- Have we characterized estradiol, progesterone, FSH, thyroid, ferritin, lipids first?
- Is HRT (where appropriate) the higher-yield first conversation than peptides?
- If we add peptides, can we sequence rather than stack on day one?
- What's the 12-week reassessment going to look like?
- What's the off-ramp from each component if response isn't what we hoped?
Sources